ClinicalTrials.gg
RecruitingNCT05410782Updated Apr 8, 2025

Power Prenatal Supplements for Sperm Quality

An interventional study of Power Prenatal for Sperm in Spermatogenesis and Semen Disorders and Infertility, Male, sponsored by The Bird and Be Co Inc. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by The Bird and Be Co Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Male factor infertility is a leading cause of primary and secondary infertility. Poor sperm quality is defined as having an abnormal semen analysis [WHO 2020 - https://www.who.int/publications/i/item/9789240030787]. The effects of supplements (vitamins, minerals, and anti-oxidants) on improving sperm quality are still debated (https://pubmed.ncbi.nlm.nih.gov/30462179). Taking additional supplements to improve sperm quality represent a modifiable risk-factor that would be an easy intervention for patients struggling with male factor infertility. The life cycle of sperm production is estimated at 3 months, so any intervention would require a 3 month course to see its full effect.

The investigators hypothesize that a 90 day course of the "Power Prenatal for Sperm", a male fertility supplement by Bird\&Be (https://birdandbe.com/the-power-prenatal-for-sperm) will improve sperm quality based on semen analysis results prior to, and after taking the supplements.

Read the detailed description

Male patients presenting to Conceive Health (https://conceivehealth.com/) or Reproductive Care Centre for infertility care will be potential candidates for this study. Male patients that have had a recent abnormal semen analysis conforming at least 1 of 3 parameters (low concentration: \< 15 Million / mL; low progressive motility \< 30%, and low morphology with strict criteria \< 4%) will be eligible to participate.

Patients will be approached by a study coordinator to participate in the study. The study coordinator will ensure all inclusion and exclusion criteria is met, consents forms are signed, and a 90 day course of the "Power Prenatal for Sperm" is dispensed

Study participants will be instructed to repeat a semen analysis (at the same lab) after their 90 day course of the "Power Prenatal for Sperm". The differences between the semen analysis parameters will be compared

The primary outcome was chosen as processive motility, as this parameter is mostly likely to be positively impacted by the Power Prenatal for Sperm.

An abnormal progressive motility is defined as \<5th percentile (32%) of the semen analysis of the fertile male population. The standard deviation for this population is 13.5%. The estimated effect size is 37.5%, from 32% to 44%, an increase of 12%. The alpha (type 1 error) significant level was set at 5% and the power level was set at 80%. The required sample size was 40 patients. Given that this study requires a 3 month intervention prior to a follow up semen analysis for comparison, the investigators estimated a 20% drop-out rate, so the total requirement was set at 50 patients.

Table A1.2 (https://www.who.int/docs/default-source/reproductive-health/srhr-documents/infertility/examination-and-processing-of-human-semen-5ed-eng.pdf)

Statistical analyses will be performed using standard expected methods. All data will be presented as mean ± Standard Deviation (SD). Statistical significance between semen analysis data will be determined by using the Shapiro-Wilk test of normality for predictions and paired samples t-test.

02

Conditions studied

  • Spermatogenesis and Semen Disorders
  • Infertility, Male

Browse trials for

03

In context

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

This study's planned enrollment of 50 is below the median of 80 across 188 interventional studies indexed under Infertility, Male.

Browse Infertility, Male studies →

Lead sponsor

The Bird and Be Co Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Age 18-45 years old
  • Experiencing infertility
  • A recent semen analysis confirming low count, motility or morphology (at least 1 of 3) - within last 3 months

    1. Low concentration: \< 15 Million / mL
    2. Low Motility: Progessive Motility \< 30%
    3. Morphology: Strict criteria: Normal forms \< 4% Reference: WHO 2020 6th edition: https://www.who.int/publications/i/item/9789240030787

Exclusion criteria

Exclusion Criteria:

  • No diagnosed varicocele
  • Younger than 18 years old
  • Older than 45 years old
  • Currently taking any form of antioxidant supplements(in last 3 months) besides a general multivitamin
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Power Prenatal for Sperm

    This is a single arm study. Participants will take supplements for 3 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)

    Dietary Supplement: Power Prenatal for Sperm

Interventions

  • Dietary supplementPower Prenatal for Sperm

    A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)

    Also known as: Prenatal Vitamins

06

What researchers measure

Primary outcomes

  1. Sperm Progressive Motility (Semen Analysis); as percentage (%)

    Semen analysis

    Time frame: A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention

Secondary outcomes

  1. Sperm Concentration (Semen Analysis); as millions / mL

    Semen analysis

    Time frame: A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention

  2. Sperm Morphology (Semen Analysis); as percentage (%)

    Semen Analysis

    Time frame: A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention

07

Study locations

1 of 1 sites recruiting
  • Reproductive Care Centre
    Mississauga, Ontario L5N 5S3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 93 interventional studies with no phase under Infertility, Male, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2022
First posted
Jun 8, 2022
StartActual
Nov 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05410782
Lead sponsor
The Bird and Be Co Inc
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Nov 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 8, 2025

Study contacts

Dan Nayot, Bsc, MSc, MD
Contact
dan@birdandbe.com
4166163334
Dan Nayot, BSc, MSc, MD
principal investigator · The Bird and Be Co

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion